Serotonin 5-HT1B/1D Receptor Agonists in Migraine

@article{Goadsby1998Serotonin5R,
  title={Serotonin 5-HT1B/1D Receptor Agonists in Migraine},
  author={Peter J. Goadsby},
  journal={CNS Drugs},
  year={1998},
  volume={10},
  pages={271-286}
}
  • P. Goadsby
  • Published 1 October 1998
  • Medicine
  • CNS Drugs
The development and clinical use of the serotonin 5-HT1 receptor agonists, collectively known as the ‘triptans’, has ushered in a new age for clinicians treating patients with migraine, as well as a new era for those who respond to the medicines. The triptans that are currently in use (sumatriptan, naratriptan, rizatriptan and zolmitriptan) and those in development [almotriptan, eletriptan and frovatriptan (SB-209509, VML-251)] all share a common pharmacology of 5-HT1B/1D receptor agonist… 
The Triptans
TLDR
All triptans cause narrowing of arteries, including coronary arteries, and although serious adverse vascular events are very rare, triptan use is contraindicated in patients with vascular disease.
Association Between Sumatriptan Treatment During a Migraine Attack and Central 5-HT1B Receptor Binding.
TLDR
A finding that is most likely associated with the binding of sumatriptan to central 5-HT1B receptors, but the contribution of ongoing cerebral serotonin release to the lower binding cannot be excluded could indicate that migraine attacks are associated with increases in endogenous serotonin.
Clinical pharmacology of the serotonin receptor agonist, zolmitriptan
TLDR
Zolmitriptan is generally very well tolerated and less than half of patients in clinical trials have reported adverse events, most of which are mild and transient, although rare serious cardiovascular events have been reported with all triptans.
Rizatriptan: a new 5-HT1B/1D receptor agonist for the treatment of migraine.
TLDR
Rizatriptan is an effective and well-tolerated acute treatment for migraine, which may offer some advantages over oral sumatripta, which has a shorter Tmax and greater bioavailability.
Clinically Significant Drug Interactions with Agents Specific For Migraine Attacks
TLDR
Nearly all the clinically important interactions between the ergopeptide antimigraine agents and currently marketed drugs are likely to have already come to notice.
Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials
BACKGROUND The triptans, selective serotonin 5-HT(1B/1D) agonists, are very effective acute migraine drugs with a well- developed scientific rationale. Seven different triptans will soon be
Novel serotonergic and non-serotonergic migraine headache therapies
TLDR
This article highlights and reviews the research advances published in patent literature between January 1997 through November 2000 and focuses on serotonergic agents, namely seratonin (5-hydroxytryptamine, 5-HT) receptor subtype agonists, drug combinations (e.g., 5- HT1D agonists with COX-2 inhibitors or NSAIDs), tachykinin receptor (NK1) antagonists and GABAergic agents.
4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT1B/1D receptor agonist activity?
TLDR
Given that 4991W93 is inactive clinically at non-vascular doses, it seems clear that the 5HT(1B/1D) agonist effects of the compound are necessary for blockade of CGRP release and thus any anti-migraine action.
Preclinical Studies Characterizing the Anti-Migraine and Cardiovascular Effects of the Selective 5-HT1D Receptor Agonist PNU-142633
TLDR
The present study describes the preclinical pharmacology of a highly selective 5-HT1Dreceptor agonist PNU-142633, which was equally effective and a half-log more potent than sumatriptan in preventing plasma protein extravasation induced by electrical stimulation of the trigeminal ganglion.
Donitriptan, a Unique High-Efficacy 5-HT1B/1D Agonist: Key Features and Acute Antimigraine Potential
TLDR
Donitriptan is a selective, potent 5-HT1B/1D receptor agonist which can be distinguished from tryptamine derivatives in consistently exerting high intrinsic activity at these receptors in a series of vascular and neuronal models relevant to migraine.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 100 REFERENCES
Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine ?
TLDR
It is demonstrated that systemically administered zolmitriptan can inhibit evoked trigeminovascular activity within the trigeminal nucleus, which may play a role in the anti‐migraine actions of this compound and offers the prospect of a third pathophysiologically consistent target site for anti‐Migraine drug effects.
Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288
TLDR
It is demonstrated that the potent inhibitor of PPE, CP122, 288, which has been shown in clinical trials to be ineffective in treating acute migraine attacks, had no effect on CGRP release, whereas the effective anti-migraine drug and relatively impotent inhibitor ofPPE, avitriptan, blocked C GRP release.
Substance P blockade with the potent and centrally acting antagonist GR205171 does not effect central trigeminal activity with superior sagittal sinus stimulation 1 These data were presented in preliminary form to the 8th International Headache Congress, Amsterdam, June 1997.[26] 1
TLDR
Data from this study suggest that neurokinin-1 blockade alone will not be an effective anti-migraine strategy, and that further data will be required to assess whether neurokin in-1 antagonists will have any more general value in pain.
Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5ht 1b/1D receptor: A central action in migraine?
TLDR
Data indicate that 5HT inhibits evoked trigeminal nucleus firing via the 5HT 1B/1D receptor at which GRI127935 is an antagonist, which highlights the case for describing this class of headache as neurovascular headaches rather than vascular headaches, to recognize the implicit contribution of the trigeminovascular system to their pathophysiology.
Is migraine prophylactic activity caused by 5-HT2B or 5-HT2C receptor blockade?
TLDR
The evidence available does not allow one to distinguish between 5-HT2C and 5- HT2B receptor blockade as possible mechanisms for prophylactic activity.
311C90 (Zolmitriptan), A Novel Centrally and Peripheral Acting Oral 5-Hydroxytryptamine-1D Agonist: A Comparison of Its Absorption During A Migraine Attack and in A Migraine-Free Period
The oral absorption of a 10-m. oral dose of the novel 5-hydroxytryptamine (5HT1D) agonist, 311C90, was compared during a moderate or severe migraine headache and in a migraine-free period in an open,
Differential Distribution of 5Ht1D-and 5HT1B-Immunoreactivity within the Human Trigemino-Cerebrovascular System: Implications for the Discovery of New Antimigraine Drugs
TLDR
A differential distribution of these receptor subtypes within the human trigemino-cerebrovascular system is demonstrated using 5HT1D- and5HT1B-receptor-specific antibodies and has important implications for the design of new antimigraine drugs.
Preclinical studies on the anti-migraine drug, sumatriptan.
TLDR
The passage of sumatriptan and its metabolites across the blood-brain barrier appeared to be very limited, although some drug could be detected in the cerebrospinal fluid after administration of high intravenous doses.
Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study.
TLDR
Together, these studies show that DHE can inhibit activity in central trigeminal neurons, implying that drugs acting at the central trigEMinal neurons may have a role in the treatment of acute attacks of migraine.
Direct Evidence for Central Sites of Action of Zolmitriptan (311C90)
TLDR
Ex vivo and in vitro data confirm the existence of a population of receptors that specifically bind zolmitriptan following systemic administration and reinforce the importance of central trigeminal neurons as a possible site of action of anti-migraine drugs.
...
1
2
3
4
5
...